Genmab — Oktober 2018
-
væksten var egentlig 16% RoW, men viser en negativ vækst på omkring 15% pga one time adjustment
-
kommunikation fra JJ og GEN nærmer sig det kriminelle
-
det er sgu lige før vi skal til at tale om ledelsesudskiftning i selskabrete
-
Er der givet rabatter, eller hvordan hænger det sammen JV?
-
jeg er ikke optimist - læs meddelelsen
-
det er simpelthen kriminelt ringe det her!
-
spændende om vi kan holde dne nedre del af guidance nu
-
de skriver i meddelelsen :"one-time adjustment outside the
U.S. related to accruals for retroactive pricing adjustments which
negatively impacted this worldwide operational growth by 16 percentage
points" -
@Thetreble, hvad mener du med at der er fusket med fase 2 resultaterne?
-
men de 16% point er vist ifht Q3 sidste år - så væksten skulle have heddet 75% ifht Q32017
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind